Achilles Therapeutics
London
About Achilles Therapeutics
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Total funding: $213.0M
- Funding stage: IPO
- Last round: Grant (Jul 2022)
- Ticker: nasdaq:ACHL
- Website: achillestx.com
- Phone: +44 (0)1438 906 906
Industries & Categories
Biotechnology, Health Care, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/achilles-therapeutics-63278 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.